女性癌症患者抑郁症状评估：关注同时效度。
Assessment of depression symptoms in female cancer patients: focus on concurrent validity.
机构信息
1Department of Health Sciences, Psychology and Psychiatry Unit, University of Florence, Florence, Italy.
Department of Health Sciences, Psychology and Psychiatry Unit, University of Florence, Florence, Italy .
出版信息
Acta Biomed. 2020 Mar 13;91(2-S):16-18. doi: 10.23750/abm.v91i2-S.9285.
BACKGROUND AND AIM OF THE WORK
The present research explores Concurrent Validity of two depression measures the Beck Depression Inventory (BDI) and the Depression Subscale of the Hospital Anxiety and Depression Scale (HADS- Depression subscale) in specific oncological groups (female cancer and onco-hematological patients).
METHOD
A correlational study was designed and took place at Careggi Universitary Hospital in Florence, including 339 oncological patients, in particular 103 (59 Women and 44 men) patients suffering from lymphoma, and 236 patients suffering from female cancer. We estimated, by Pearson's r, Concurrent Validity between BDI and HADS depression's subscale.
RESULTS
Correlations failed to reach the 0.55 cut-off in the female cancer group (r=.34, p<.001) but not in the onco-hematological patients (r= 0.56, p<.001).
CONCLUSION
The results stressing the need to develop and validate assessing tools that are specifically devoted to different groups of oncological patients. (www.actabiomedica.it).
背景和工作目的
本研究旨在探讨贝克抑郁量表（BDI）和医院焦虑和抑郁量表（HADS-抑郁分量表）这两种抑郁测量方法在特定肿瘤患者群体（女性癌症和肿瘤血液病患者）中的同时效度。
方法
采用相关性研究设计，在佛罗伦萨的 Careggi 大学医院进行，共纳入 339 名肿瘤患者，其中 103 名（59 名女性和 44 名男性）患有淋巴瘤，236 名患有女性癌症。我们通过 Pearson r 估计了 BDI 和 HADS 抑郁分量表之间的同时效度。
结果
相关性在女性癌症组中未达到 0.55 的截止值（r=.34，p<.001），但在肿瘤血液病患者组中达到了（r= 0.56，p<.001）。
结论
这些结果强调了需要开发和验证专门针对不同肿瘤患者群体的评估工具的必要性。（www.actabiomedica.it）。
Zotero 插件